Birdwatch Note
2025-01-14 06:57:28 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Studies have shown Ivermectin has powerful antitumor effects, including inhibition of proliferation, metastasis, and angiogenic activity in various cancer cells. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/ It was found Ivermectin could reverse resistance of cancer cells to chemo drugs both in vitro and in vivo. https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7
Written by B7F9FE427BF545D88BC022D9AE0E78CA96857EC42B5504625658C693595E3F86
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1877819687821594661
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1879060246515384627
- noteId - 1879060246515384627
- participantId -
- noteAuthorParticipantId - B7F9FE427BF545D88BC022D9AE0E78CA96857EC42B5504625658C693595E3F86
- createdAtMillis - 1736837848677
- tweetId - 1877819687821594661
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Studies have shown Ivermectin has powerful antitumor effects, including inhibition of proliferation, metastasis, and angiogenic activity in various cancer cells. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505114/ It was found Ivermectin could reverse resistance of cancer cells to chemo drugs both in vitro and in vivo. https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1251-7
Note Ratings
rated at | rated by | |
2025-01-14 19:59:09 -0600 | Rating Details | |
2025-01-14 19:57:59 -0600 | Rating Details | |
2025-01-14 19:31:49 -0600 | Rating Details | |
2025-01-14 18:32:01 -0600 | Rating Details | |
2025-01-14 18:30:20 -0600 | Rating Details | |
2025-01-14 18:24:41 -0600 | Rating Details | |
2025-01-14 18:11:01 -0600 | Rating Details | |
2025-01-14 18:03:06 -0600 | Rating Details | |
2025-01-14 17:53:02 -0600 | Rating Details | |
2025-01-14 17:48:13 -0600 | Rating Details | |
2025-01-14 17:46:08 -0600 | Rating Details | |
2025-01-14 17:39:43 -0600 | Rating Details | |
2025-01-14 17:36:10 -0600 | Rating Details | |
2025-01-14 17:25:10 -0600 | Rating Details | |
2025-01-14 17:22:19 -0600 | Rating Details | |
2025-01-14 17:17:26 -0600 | Rating Details | |
2025-01-14 16:47:13 -0600 | Rating Details | |
2025-01-14 15:35:28 -0600 | Rating Details | |
2025-01-14 15:15:30 -0600 | Rating Details | |
2025-01-14 15:10:00 -0600 | Rating Details | |
2025-01-14 14:30:48 -0600 | Rating Details | |
2025-01-14 14:28:09 -0600 | Rating Details | |
2025-01-14 14:19:30 -0600 | Rating Details | |
2025-01-14 14:07:04 -0600 | Rating Details | |
2025-01-14 14:00:46 -0600 | Rating Details | |
2025-01-14 13:08:53 -0600 | Rating Details | |
2025-01-14 12:43:09 -0600 | Rating Details | |
2025-01-14 12:27:09 -0600 | Rating Details | |
2025-01-14 12:17:02 -0600 | Rating Details | |
2025-01-14 11:30:19 -0600 | Rating Details | |
2025-01-14 11:20:39 -0600 | Rating Details | |
2025-01-14 11:15:20 -0600 | Rating Details | |
2025-01-14 10:26:23 -0600 | Rating Details | |
2025-01-14 10:05:39 -0600 | Rating Details | |
2025-01-14 10:05:17 -0600 | Rating Details | |
2025-01-14 09:50:26 -0600 | Rating Details | |
2025-01-14 09:39:23 -0600 | Rating Details | |
2025-01-14 09:35:24 -0600 | Rating Details | |
2025-01-14 09:29:21 -0600 | Rating Details | |
2025-01-14 08:57:08 -0600 | Rating Details | |
2025-01-14 08:53:44 -0600 | Rating Details | |
2025-01-14 08:44:06 -0600 | Rating Details | |
2025-01-14 08:13:23 -0600 | Rating Details | |
2025-01-14 07:58:16 -0600 | Rating Details | |
2025-01-14 07:54:06 -0600 | Rating Details | |
2025-01-14 07:53:19 -0600 | Rating Details | |
2025-01-14 07:45:39 -0600 | Rating Details | |
2025-01-14 07:44:48 -0600 | Rating Details | |
2025-01-14 07:43:15 -0600 | Rating Details | |
2025-01-14 07:42:02 -0600 | Rating Details | |
2025-01-14 07:39:24 -0600 | Rating Details | |
2025-01-14 07:35:33 -0600 | Rating Details | |
2025-01-14 07:29:13 -0600 | Rating Details | |
2025-01-14 07:28:34 -0600 | Rating Details | |
2025-01-14 07:10:35 -0600 | Rating Details | |
2025-01-14 07:02:17 -0600 | Rating Details | |
2025-01-14 06:30:35 -0600 | Rating Details | |
2025-01-14 06:17:51 -0600 | Rating Details | |
2025-01-14 06:08:22 -0600 | Rating Details | |
2025-01-14 05:52:48 -0600 | Rating Details | |
2025-01-14 05:42:02 -0600 | Rating Details | |
2025-01-14 05:32:41 -0600 | Rating Details | |
2025-01-14 05:23:13 -0600 | Rating Details | |
2025-01-14 05:17:05 -0600 | Rating Details | |
2025-01-14 05:12:18 -0600 | Rating Details | |
2025-01-14 04:58:38 -0600 | Rating Details | |
2025-01-14 04:57:44 -0600 | Rating Details | |
2025-01-14 04:45:29 -0600 | Rating Details | |
2025-01-14 04:30:00 -0600 | Rating Details | |
2025-01-14 04:27:22 -0600 | Rating Details | |
2025-01-14 04:25:14 -0600 | Rating Details | |
2025-01-14 04:14:49 -0600 | Rating Details | |
2025-01-14 03:53:39 -0600 | Rating Details | |
2025-01-14 03:38:21 -0600 | Rating Details | |
2025-01-14 03:37:17 -0600 | Rating Details | |
2025-01-14 03:19:26 -0600 | Rating Details | |
2025-01-14 02:51:35 -0600 | Rating Details | |
2025-01-14 02:50:46 -0600 | Rating Details | |
2025-01-14 02:46:07 -0600 | Rating Details | |
2025-01-14 02:37:40 -0600 | Rating Details | |
2025-01-14 02:33:19 -0600 | Rating Details | |
2025-01-14 02:30:06 -0600 | Rating Details | |
2025-01-14 02:20:39 -0600 | Rating Details | |
2025-01-14 02:16:42 -0600 | Rating Details | |
2025-01-14 02:16:11 -0600 | Rating Details | |
2025-01-14 01:51:17 -0600 | Rating Details | |
2025-01-14 01:49:00 -0600 | Rating Details | |
2025-01-14 01:45:00 -0600 | Rating Details | |
2025-01-14 01:34:03 -0600 | Rating Details | |
2025-01-14 01:29:50 -0600 | Rating Details | |
2025-01-14 01:26:14 -0600 | Rating Details | |
2025-01-14 01:24:38 -0600 | Rating Details | |
2025-01-14 01:18:27 -0600 | Rating Details | |
2025-01-14 01:14:10 -0600 | Rating Details | |
2025-01-14 01:06:12 -0600 | Rating Details | |
2025-01-17 22:42:03 -0600 | Rating Details | |
2025-01-16 23:19:33 -0600 | Rating Details | |
2025-01-16 20:12:17 -0600 | Rating Details | |
2025-01-16 20:02:13 -0600 | Rating Details | |
2025-01-15 23:59:12 -0600 | Rating Details | |
2025-01-15 21:28:26 -0600 | Rating Details | |
2025-01-15 20:08:55 -0600 | Rating Details | |
2025-01-15 15:26:05 -0600 | Rating Details | |
2025-01-15 14:58:48 -0600 | Rating Details | |
2025-01-15 13:41:53 -0600 | Rating Details | |
2025-01-15 13:22:10 -0600 | Rating Details | |
2025-01-15 13:21:12 -0600 | Rating Details | |
2025-01-15 12:28:56 -0600 | Rating Details | |
2025-01-15 11:48:00 -0600 | Rating Details | |
2025-01-15 10:26:59 -0600 | Rating Details | |
2025-01-15 10:01:29 -0600 | Rating Details | |
2025-01-15 08:43:12 -0600 | Rating Details | |
2025-01-15 08:37:19 -0600 | Rating Details | |
2025-01-15 08:04:31 -0600 | Rating Details | |
2025-01-15 08:00:20 -0600 | Rating Details | |
2025-01-15 06:56:45 -0600 | Rating Details | |
2025-01-14 23:09:10 -0600 | Rating Details | |
2025-01-14 22:56:23 -0600 | Rating Details | |
2025-01-14 22:17:46 -0600 | Rating Details | |
2025-01-14 22:10:52 -0600 | Rating Details | |
2025-01-14 21:32:18 -0600 | Rating Details | |
2025-01-14 21:24:33 -0600 | Rating Details | |
2025-01-14 20:47:52 -0600 | Rating Details | |
2025-01-14 20:09:50 -0600 | Rating Details | |
2025-01-18 08:20:56 -0600 | Rating Details | |
2025-01-16 11:41:47 -0600 | Rating Details | |
2025-01-15 23:05:00 -0600 | Rating Details | |
2025-01-15 18:43:33 -0600 | Rating Details | |
2025-01-15 16:12:52 -0600 | Rating Details | |
2025-01-15 15:31:42 -0600 | Rating Details | |
2025-01-15 12:19:37 -0600 | Rating Details | |
2025-01-15 05:13:10 -0600 | Rating Details | |
2025-01-15 02:38:57 -0600 | Rating Details | |
2025-01-15 01:44:35 -0600 | Rating Details | |
2025-01-14 20:33:24 -0600 | Rating Details | |
2025-01-14 20:20:14 -0600 | Rating Details | |
2025-01-14 18:54:41 -0600 | Rating Details | |
2025-01-14 17:58:58 -0600 | Rating Details | |
2025-01-14 17:50:16 -0600 | Rating Details | |
2025-01-14 17:41:30 -0600 | Rating Details | |
2025-01-14 17:27:29 -0600 | Rating Details | |
2025-01-14 17:07:24 -0600 | Rating Details | |
2025-01-14 15:49:33 -0600 | Rating Details | |
2025-01-14 15:25:30 -0600 | Rating Details | |
2025-01-14 15:05:51 -0600 | Rating Details | |
2025-01-14 14:04:42 -0600 | Rating Details | |
2025-01-14 13:16:02 -0600 | Rating Details | |
2025-01-14 13:15:54 -0600 | Rating Details | |
2025-01-14 13:09:11 -0600 | Rating Details | |
2025-01-14 11:42:24 -0600 | Rating Details | |
2025-01-14 11:34:16 -0600 | Rating Details | |
2025-01-14 09:26:00 -0600 | Rating Details | |
2025-01-14 09:24:10 -0600 | Rating Details | |
2025-01-14 09:06:21 -0600 | Rating Details | |
2025-01-14 08:44:05 -0600 | Rating Details | |
2025-01-14 08:28:59 -0600 | Rating Details | |
2025-01-14 07:54:49 -0600 | Rating Details | |
2025-01-14 07:48:42 -0600 | Rating Details | |
2025-01-14 07:42:55 -0600 | Rating Details | |
2025-01-14 07:15:14 -0600 | Rating Details | |
2025-01-14 06:52:36 -0600 | Rating Details | |
2025-01-14 06:29:35 -0600 | Rating Details | |
2025-01-14 06:09:01 -0600 | Rating Details | |
2025-01-14 06:08:31 -0600 | Rating Details | |
2025-01-14 04:54:57 -0600 | Rating Details | |
2025-01-14 04:25:46 -0600 | Rating Details | |
2025-01-14 02:17:01 -0600 | Rating Details | |
2025-01-14 02:01:19 -0600 | Rating Details | |
2025-01-14 01:47:37 -0600 | Rating Details | |
2025-01-14 01:40:42 -0600 | Rating Details |